Expert consensus on diagnosis and treatment of malignant pleural effusion caused by lung cancer.
10.3760/cma.j.cn112152-20231130-00344
- Collective Name:China Association of Health Promotion and Education;Cancer Rehabilitation and Palliative Treatment Professional Committee of China Anti-Cancer Association
- Publication Type:Journal Article
- MeSH:
Humans;
Lung Neoplasms/diagnosis*;
Pleural Effusion, Malignant/therapy*;
Consensus;
Quality of Life;
Pleural Effusion/therapy*
- From:
Chinese Journal of Oncology
2024;46(1):40-47
- CountryChina
- Language:Chinese
-
Abstract:
Malignant pleural effusion (MPE) can occur in nearly all types of malignant tumors, with lung cancer being the most prevalent cause. The presence of MPE indicates an advanced stage or distant spread of the tumor, significantly reducing the patient's life expectancy. Particularly, a substantial amount of pleural effusion can impede heart and lung function, impair blood oxygen perfusion levels in the body, and greatly diminish patients' quality of life. Even when systemic treatment has alleviated the primary lung tumor in some patients, effective control over MPE remains challenging and impacts clinical outcomes. Therefore, it is crucial to implement measures for reducing or managing MPE while ensuring standardized treatment for lung cancer. In recent years, significant advancements have been made in diagnosing and treating lung cancer complicated by MPE through extensive basic and clinical research. Based on existing evidence and China's clinical practice experience, relevant experts from the China Association of Health Promotion and Education and Cancer Rehabilitation and Palliative Treatment Professional Committee of China Anti-Cancer Association (CRPC) have summarized key aspects related to diagnosis and treatment consensus opinions for lung cancer complicated by MPE. This aims to establish standardized procedures that will serve as a reference for doctors' clinical practice.
